HC Wainwright Issues Pessimistic Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price

BiomX (NYSEAMERICAN:PHGE) had its price objective reduced by equities research analysts at HC Wainwright from $21.00 to $15.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

BiomX Price Performance

NYSEAMERICAN PHGE opened at $0.54 on Friday. The stock has a 50-day simple moving average of $0.57. The company has a market cap of $9.82 million, a P/E ratio of -0.17 and a beta of 1.27. BiomX has a one year low of $0.48 and a one year high of $4.90.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).